ALDH2 rs671 Variant Lowers Blood Pressure Via the Endothelial HSPA5–PIEZO1–eNOS Pathway
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.124.040121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Huaqing Ye und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine Qilu Hospital of Shandong University Jinan China. Hauptthemen laut MEDLINE: Aldehyde Dehydrogenase, Mitochondrial, Nitric Oxide Synthase Type III, Hypertension, Blood Pressure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The inactivating ALDH2 rs671 polymorphism, present in ≈8% of the global population and up to 30% to 50% of East Asian individuals, has been negatively associated with hypertension. However, the direct role of ALDH2 (aldehyde dehydrogenase 2) dysfunction in this association, as well as the underlying mechanisms by which ALDH2 rs671 influences blood pressure regulation, remains unclear.
Methods
Using Aldh2 E506K (equivalent to the human ALDH2 rs671 polymorphism), Aldh2 global knockout, and endothelial cell‐specific Aldh2 knockout mice, we assessed changes in blood pressure (BP) using both telemetry and tail‐cuff methods. Mass spectrometry, coimmunoprecipitation, and other biological techniques were used to elucidate underlying molecular mechanisms.
Results
Aldh2 E506K or Aldh2 global knockout mice displayed a significant decrease in BP under both physiological conditions and angiotensin II–induced hypertension, independent of changes in cardiac output and renal function. Mechanistic studies revealed that endothelial ALDH2 dysfunction inhibited the lysosomal degradation of PIEZO1 (piezo‐type mechanosensitive ion channel component 1), resulting in its upregulated protein level and activation of the PIEZO1–endothelial nitric oxide synthase BP regulatory axis. PIEZO1 knockdown or channel inhibition by Grammostola spatulata mechanotoxin 4 peptide reversed the reduced BP phenotype exhibited by Aldh2 ECKO mice. Using coimmunoprecipitation combined with mass spectrometry, the molecular chaperone HSPA5 (heat shock protein family A member 5) was identified as a novel interactor with PIEZO1, binding to its C‐terminus. HSPA5, induced by aldehyde accumulation, functionally enhanced PIEZO1 protein stability upon ALDH2 loss‐of‐function mutation. Endothelial‐specific overexpression of HSPA5 could alleviate angiotensin II–induced hypertension in mice.
Conclusions
Our study provides definitive experimental evidence that ALDH2 rs671 variation or endothelial Aldh2 deficiency plays a protective role in BP regulation by activating the HSPA5–PIEZO1–endothelial nitric oxide synthase axis. We also revealed the previously unrecognized role of HSPA5 in maintaining PIEZO1 stability and BP regulation, providing a potential novel intervention target for hypertension therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine Qilu Hospital of Shandong University Jinan China.
- Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Chest Pain Center Qilu Hospital of Shandong University Jin…
- Medical and Pharmaceutical Basic Research Innovation Center of Emergency and Critical Care Medicine, China's Ministry of Education, Shandong Provincial Engineering Laboratory for Emergency and Critical Care Medicine, Ke…
- NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug Qilu Hospital of Shandong University Jinan China.
- National Key Laboratory for Innovation and Transformation of Luobing Theory, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and C…
ORCID-Profile: Hongwei Yue, Shujian Wei, Kehui Yang, Han Du, Wentao Sang, Jialin Guo, Jingwen Wang, Cheng Zhang, Sumei Cui, Feng Xu, Yuguo Chen
Zitieren
APA
Ye, H., Yue, H., Wei, S., Wang, K., Yang, K., Du, H., Sang, W., Guo, J., Wang, J., Guo, Y., Zhang, C., Cui, S., Xu, F., & Chen, Y. (2026). ALDH2 rs671 Variant Lowers Blood Pressure Via the Endothelial HSPA5–PIEZO1–eNOS Pathway. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.040121
Vancouver
Ye H, Yue H, Wei S, Wang K, Yang K, Du H, et al. ALDH2 rs671 Variant Lowers Blood Pressure Via the Endothelial HSPA5–PIEZO1–eNOS Pathway. Journal of the American Heart Association. 2026. doi:10.1161/jaha.124.040121
BibTeX
@article{Ye2026,
author = {Ye, Huaqing and Yue, Hongwei and Wei, Shujian and Wang, Kaiyi and Yang, Kehui and Du, Han and Sang, Wentao and Guo, Jialin and Wang, Jingwen and Guo, Yunyun and Zhang, Cheng and Cui, Sumei and Xu, Feng and Chen, Yuguo},
title = {ALDH2 rs671 Variant Lowers Blood Pressure Via the Endothelial HSPA5–PIEZO1–eNOS Pathway},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.124.040121}
}
EUVIMED